BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:ONLINE WEBINAR - The Breath Biopsy® Platform  - Billy Boyle\, Owl
 stone.
DTSTART:20210311T183000Z
DTEND:20210311T193000Z
UID:TALK153370@talks.cam.ac.uk
CONTACT:David Blake
DESCRIPTION:Cancer killed 8.8 million people in 2015 alone. It is a stark 
 reality that 1 in 2 of us will get cancer. From our parents to our partner
 s\, our children\, our grandchildren - 1 in 2 will get cancer. We must fin
 d better ways to treat cancer\, but more importantly better ways to detect
  cancer earlier\, when chances of a cure are dramatically higher.\nEvery t
 ime you breathe out there are thousands of chemicals on your breath\, some
  of these are markers of cancer.\nThis talk will provide an overview of th
 e research currently being undertaken in Cambridge by Owlstone Medical Ltd
  using our Breath Biopsy® platform to “sniff” out these chemical mark
 ers to detect cancer earlier.\nOur greatest opportunity lies not in develo
 ping new drugs but increasing rates of early diagnosis through improved ca
 ncer screening. \n\nSpeaker Profile\nBilly Boyle is an engineering graduat
 e from the University of Cambridge. He is one of the original co-founders 
 of Owlstone Inc\, spun out of Cambridge in 2004\, which has raised $28M in
  investment and won >$25M in defence contracts. He initially worked with s
 ilicon foundries in the design and fabrication of the core microchip techn
 ology and is co-inventor on 19 patents. He then assumed a commercial role 
 with P&L responsibility for the Scientific Instruments and Industrial busi
 ness units\; responsible for sales of FAIMS products and contracts with >1
 50 clients globally\, including Agilent\, Thermo\, Roche Diagnostics\, Sam
 sung\, GSK\, 4D Pharma\, Mayo Clinic and the NHS.\nBilly started to focus 
 on the medical applications of FAIMS technology after his wife\, Kate\, wa
 s diagnosed and later died of colon cancer as a result of a late diagnosis
 . He worked closely with clinical partners who integrated FAIMS technology
  across a broad spectrum of clinical trials in cancer\, inflammatory disea
 se & infectious disease.\nAfter positive clinical trial results he headed 
 up the newly formed Medical business unit\, which won a £1M NHS contract 
 for LuCID to use FAIMS technology in the early detection of lung cancer. W
 ith ongoing clinical and commercial success\, Billy led the process to spi
 n out Owlstone Medical Ltd and became the founding CEO upon the close of a
  $7M investment in March 2016. The mission of Owlstone Medical is to save 
 100\,000 lives and $1.5B in healthcare costs.\nBilly was made a Fellow of 
 the Royal Academy of Engineering in 2020. \n\nTo make a booking please go 
 to https://localevents.theiet.org/bb846e
LOCATION: Webinar  (via Zoom online)- link to follow
END:VEVENT
END:VCALENDAR